Cullinan Therapeutics Inc. Watch

EX-10.1

from 10-Q 13 pages The Purpose of This Separation and Transition Letter Agreement (This “Agreement”) Is to Confirm the Terms of Your Separation From Cullinan Oncology, Inc. (The “Company”) and Your Post-Separation Consulting Arrangement With the Company. Capitalized Terms Not Defined Herein Shall Have the Respective Meanings Ascribed to Them in the Employment Agreement Between You and the Company Dated January 7, 2021 (The “Employment Agreement”). 1. Transition Period and Separation Date

12/34/56

EX-10.1

from 8-K 16 pages Employment Agreement

12/34/56

EX-10.3

from 8-K 13 pages Pre-Funded Warrant to Purchase Stock

12/34/56

EX-10.2

from 8-K 23 pages Registration Rights Agreement

12/34/56

EX-10.1

from 8-K 48 pages Stock Purchase Agreement by and Between Cullinan Therapeutics, Inc. and Each of the Purchasers as Set Forth Herein April 15, 2024

12/34/56

EX-10.32

from 10-K 4 pages Restricted Stock Unit Award Agreement for Company Employees Under the Cullinan Oncology, Inc. 2021 Stock Option and Incentive Plan

12/34/56

EX-10.1

from 10-Q 3 pages Amendment No. 1 to Employment Agreement

12/34/56

EX-10.2

from 10-Q 3 pages The Purpose of This Non-Employee Director Compensation Policy (The “Policy”) of Cullinan Oncology, Inc. (The “Company”) Is to Provide a Total Compensation Package That Enables the Company to Attract and Retain, on a Long-Term Basis, High-Caliber Directors Who Are Not Employees or Officers of the Company or Its Subsidiaries (“Outside Directors”). This Policy Is Effective as of the Adoption Date Set Forth Below (The “Effective Date”). in Furtherance of the Purpose Stated Above, All Outside Directors Shall Be Paid Compensation for Services Provided to the Company as Set Forth Below: Cash Retainers

12/34/56

EX-10.1

from 10-Q 14 pages Consulting Agreement

12/34/56

EX-10.2

from 10-Q 69 pages Certain Information Contained in This Document, Marked by [***], Has Been Omitted Because It (I) Is Not Material and (II) Is the Type of Information That the Registrant Typically Treats as Private or Confidential. License and Collaboration Agreement by and Between Harbour Biomed US Inc. and Cullinan Oncology, Inc. Dated as of February , 2023

12/34/56

EX-10

from 10-K 4 pages Amendment Number 1 to Royalty Transfer Agreement

12/34/56

EX-10

from 10-K 3 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to Cullinan Oncology, Inc. if Publicly Disclosed. Massachusetts Institute of Technology and Cullinan Amber Corp. Second Amendment

12/34/56

EX-10

from 10-K 12 pages [Option] Purchase and Transfer Agreement

12/34/56

EX-10

from 10-K 13 pages Stock Purchase and Transfer Agreement

12/34/56

EX-10

from 10-K 14 pages Employment Agreement

12/34/56

EX-10.1

from 8-K 23 pages January 17, 2023 Cullinan Oncology, Inc. One Main Street, Suite 1350 Cambridge, Ma 02142 Attention: Jeffrey Trigilio Re: 3(a)(9) Exchange Agreement Ladies and Gentlemen

12/34/56

EX-10.3

from 10-Q 5 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to Cullinan Oncology, Inc. if Publicly Disclosed. Performance Stock Unit Award Agreement for Company Employees Under the Cullinan Oncology, Inc. 2021 Stock Option and Incentive Plan

12/34/56

EX-10.2

from 10-Q 90 pages Co-Development Agreement by and Between Taiho Oncology, Inc. and Cullinan Oncology, Inc. 1

12/34/56

EX-10.1

from 10-Q 74 pages Share Purchase Agreement by and Among Taiho Pharmaceutical Co., Ltd Cullinan Pearl Corp. and Cullinan Oncology, Inc May 11, 2022

12/34/56

EX-10.23

from 10-K 10 pages Separation Agreement

12/34/56